Join to View Full Profile
251 E Huron StChicago, IL 60611
Dr. Vanderweele is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2009 - 2012- University of ChicagoResidency, Internal Medicine, 2007 - 2009
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2007
Certifications & Licensure
IL State Medical License 2009 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostat...Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele, Matthew Rettig, Elisabeth I Heath
Journal of Clinical Oncology. 2025-03-26 - Response to pembrolizumab in advanced prostate cancer with predictive biomarkers.Nicole J Altomare, Yutai Li, Clayton Neill, Maha Hussain, David J VanderWeele
The Oncologist. 2025-03-10 - Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin.John S Wang, Jack C Shapiro, Sarah Orlando, Rusul Al-Marayaty, Farres Obeidin
Journal of Cancer Research and Clinical Oncology. 2025-02-10
Press Mentions
Combination Treatment Extends Survival in Advanced Bladder CancerSeptember 17th, 2024- Combination Treatment Extends Survival in Locally Advanced Bladder CancerSeptember 15th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
